These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29636106)

  • 1. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa.
    Evans D; Hirasen K; Berhanu R; Malete G; Ive P; Spencer D; Badal-Faesen S; Sanne IM; Fox MP
    AIDS Res Ther; 2018 Apr; 15(1):10. PubMed ID: 29636106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Third-Line Antiretroviral Therapy Program in the South African Public Sector: Cohort Description and Virological Outcomes.
    Moorhouse M; Maartens G; Venter WDF; Moosa MY; Steegen K; Jamaloodien K; Fox MP; Conradie F
    J Acquir Immune Defic Syndr; 2019 Jan; 80(1):73-78. PubMed ID: 30334876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in Johannesburg, South Africa.
    Fox MP; Berhanu R; Steegen K; Firnhaber C; Ive P; Spencer D; Mashamaite S; Sheik S; Jonker I; Howell P; Long L; Evans D
    Trop Med Int Health; 2016 Sep; 21(9):1131-7. PubMed ID: 27383454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa.
    Shearer K; Evans D; Moyo F; Rohr JK; Berhanu R; Van Den Berg L; Long L; Sanne I; Fox MP
    Trop Med Int Health; 2017 Feb; 22(2):221-231. PubMed ID: 27797443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
    Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
    Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the Need for Third-Line Antiretroviral Therapy by Identifying Patients at High Risk for Failing Second-Line Antiretroviral Therapy in South Africa.
    Onoya D; Nattey C; Budgell E; van den Berg L; Maskew M; Evans D; Hirasen K; Long LC; Fox MP
    AIDS Patient Care STDS; 2017 May; 31(5):205-212. PubMed ID: 28445088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes after virologic failure of first-line ART in South Africa.
    Murphy RA; Sunpath H; Lu Z; Chelin N; Losina E; Gordon M; Ross D; Ewusi AD; Matthews LT; Kuritzkes DR; Marconi VC;
    AIDS; 2010 Apr; 24(7):1007-12. PubMed ID: 20397305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa.
    Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
    PLoS One; 2016; 11(8):e0161469. PubMed ID: 27548695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social and behavioral factors associated with failing second-line ART - results from a cohort study at the Themba Lethu Clinic, Johannesburg, South Africa.
    Evans D; Dahlberg S; Berhanu R; Sineke T; Govathson C; Jonker I; Lönnermark E; Fox MP
    AIDS Care; 2018 Jul; 30(7):863-870. PubMed ID: 29463102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda.
    Ssempijja V; Nakigozi G; Chang L; Gray R; Wawer M; Ndyanabo A; Kasule J; Serwadda D; Castelnuovo B; Hoog AV; Reynolds SJ
    BMC Infect Dis; 2017 Aug; 17(1):582. PubMed ID: 28830382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa.
    Fox MP; Cutsem GV; Giddy J; Maskew M; Keiser O; Prozesky H; Wood R; Hernán MA; Sterne JA; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):428-37. PubMed ID: 22433846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
    Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
    AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line antiretroviral therapy: long-term outcomes in South Africa.
    Murphy RA; Sunpath H; Castilla C; Ebrahim S; Court R; Nguyen H; Kuritzkes D; Marconi VC; Nachega JB
    J Acquir Immune Defic Syndr; 2012 Oct; 61(2):158-163. PubMed ID: 22692090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
    Davies MA; Moultrie H; Eley B; Rabie H; Van Cutsem G; Giddy J; Wood R; Technau K; Keiser O; Egger M; Boulle A;
    J Acquir Immune Defic Syndr; 2011 Mar; 56(3):270-8. PubMed ID: 21107266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study.
    Eholie SP; Moh R; Benalycherif A; Gabillard D; Ello F; Messou E; Zoungrana J; Diallo I; Diallo M; Bado G; Cisse M; Maiga AI; Anzian A; Toni TD; Congo-Ouedraogo M; Toure-Kane C; Seydi M; Minta DK; Sawadogo A; Sangaré L; Drabo J; Karcher S; Le Carrou J; de Monteynard LA; Peytavin G; Gabassi A; Girard PM; Chaix ML; Anglaret X; Landman R;
    Lancet HIV; 2019 Nov; 6(11):e750-e759. PubMed ID: 31601544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
    Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
    Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. It is time to consider third-line options in antiretroviral-experienced paediatric patients?
    Zyl GU; Rabie H; Nuttall JJ; Cotton MF
    J Int AIDS Soc; 2011 Nov; 14():55. PubMed ID: 22085598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric response to second-line antiretroviral therapy in South Africa.
    Zanoni BC; Sunpath H; Feeney ME
    PLoS One; 2012; 7(11):e49591. PubMed ID: 23185373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.